Midwest Clinical Research Center

Summary

Midwest Clinical Research Center is a medical facility located in Dayton, Ohio. This center is recognized for care of Major Depressive Disorder, Depression, Schizophrenia, Attention-Deficit/Hyperactivity Disorder (ADHD), Bipolar Disorder and other specialties. Midwest Clinical Research Center is involved with conducting 182 clinical trials across 104 conditions. There are 3 research doctors associated with this hospital, such as Richard D Sanders, MD, Otto Dueno, MD, and Syed Najeed, MD.

Top PIs

Clinical Trials running at Midwest Clinical Research Center

Chronic Urticaria

Relapse

Motor and sensory neuropathy

Multiple Sclerosis

Systemic Lupus Erythematosus

Lupus

Vascular Skin Disorder

Skin Conditions

Immune Dysfunction

Pathology

Remibrutinib

for Chronic Urticaria

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderate to severe chronic spontaneous urticaria (CSU) inadequately controlled by sgH1-AHs.

Recruiting

1 award

Phase 3

2 criteria

Briquilimab

for Chronic Hives

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.

Recruiting

0 awards

Phase 1 & 2

9 criteria